tiprankstipranks
pc:micro

MicrobiotiX

Worcester, Massachusetts, United States
www.microbiotix.com
MicrobiotiX is a biotechnology company specializing in the development of bacteriophage-based therapeutics aimed at combating diseases caused by multidrug-resistant bacteria. The company leverages a comprehensive platform for phage therapy development, which includes a phage library panel, an in silico module, and a cGMP-grade manufacturing facility. MicrobiotiX is pioneering efforts in Korea to conduct the first human clinical trials of phage therapy, supported by government funding to advance research and development for the commercialization of these innovative anti-infective drugs.

Leadership & Board

Key Executives
Chief Scientific OfficerZachary D. Aron
Chief Business OfficerRichard Gauthier
Founder, President & CEOTerry L. Bowlin
Current Number of Employees18
Current LinkedIn Followers911

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$20B
Total Amount Raised$20B
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$20B
Latest Funding Amount$20B
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Employee Trend

MicrobiotiX had 18 employees as of April 6, 2026. The number of employees increased by 0 (0.00%) week-over-week.
18Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

MicrobiotiX had 911 followers as of April 6, 2026. The number of followers increased by 1 (0.11%) week-over-week.
911Latest Followers Count
1(0.11%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Sep 03, 2025
Series B
$20.00B

Investors

Investor Name
Funding Round

Related News and Analysis